| Sarah E Nicholas, MD | |
|
Banner Md Anderson Cancer Center, 2946 E. Banner Gateway Drive, Gilbert, AZ 85234 | |
| (480) 256-6444 | |
| (480) 256-3682 |
| Full Name | Sarah E Nicholas |
|---|---|
| Gender | Female |
| Speciality | Radiation Oncology |
| Experience | 10 Years |
| Location | Banner Md Anderson Cancer Center, Gilbert, Arizona |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104230333 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0001X | Radiology - Radiation Oncology | 58458 (Arizona) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Banner Gateway Medical Center | Gilbert, AZ | Hospital |
| Banner Boswell Medical Center | Sun city, AZ | Hospital |
| Banner Thunderbird Medical Center | Glendale, AZ | Hospital |
| Banner Del E. Webb Medical Center | Sun city west, AZ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Bhsm Rehabilitation Llc | 2062773138 | 1258 |
| Banner Cancer Center Specialists Llc | 6103097779 | 266 |
News Archive
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, presented new pre-clinical data from its ALN-TTR program at the XII International Symposium on Amyloidosis in Rome on April 18 - 21, 2010. ALN-TTR01 is a systemically delivered RNAi therapeutic being developed for the treatment of transthyretin (TTR)-mediated amyloidosis (ATTR), including familial amyloidotic polyneuropathy (FAP) and familial amyloidotic cardiomyopathy (FAC).
Auxilium Pharmaceuticals, Inc., a fully integrated specialty biopharmaceutical company, today announced financial results for the fourth quarter and full year ending December 31, 2013. The Company also highlighted select commercial, regulatory and clinical development progress and future goals and provided financial guidance for 2014.
Also, news outlets examine the idea that the expansion's new enrollees will likely be healthier than current beneficiaries but this will probably not relieve the expansion's pressure on the health care workforce.
The U.S. Food and Drug Administration has accepted an Investigational New Drug application by physician-scientists at University of California San Diego School of Medicine to conduct the first U.S. clinical trial of an intravenously administered bacteriophage-based therapy.
Therapeutic hypnosis is an effective and safe complementary technique in surgery and the treatment of irritable bowel syndrome. This is the conclusion of a systematic review by Winfried Häuser and his co-authors in the latest issue of Deutsches Ärzteblatt International.
› Verified 6 days ago
| Entity Name | Banner Cancer Center Specialists Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1518253152 PECOS PAC ID: 6103097779 Enrollment ID: O20110913000224 |
News Archive
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, presented new pre-clinical data from its ALN-TTR program at the XII International Symposium on Amyloidosis in Rome on April 18 - 21, 2010. ALN-TTR01 is a systemically delivered RNAi therapeutic being developed for the treatment of transthyretin (TTR)-mediated amyloidosis (ATTR), including familial amyloidotic polyneuropathy (FAP) and familial amyloidotic cardiomyopathy (FAC).
Auxilium Pharmaceuticals, Inc., a fully integrated specialty biopharmaceutical company, today announced financial results for the fourth quarter and full year ending December 31, 2013. The Company also highlighted select commercial, regulatory and clinical development progress and future goals and provided financial guidance for 2014.
Also, news outlets examine the idea that the expansion's new enrollees will likely be healthier than current beneficiaries but this will probably not relieve the expansion's pressure on the health care workforce.
The U.S. Food and Drug Administration has accepted an Investigational New Drug application by physician-scientists at University of California San Diego School of Medicine to conduct the first U.S. clinical trial of an intravenously administered bacteriophage-based therapy.
Therapeutic hypnosis is an effective and safe complementary technique in surgery and the treatment of irritable bowel syndrome. This is the conclusion of a systematic review by Winfried Häuser and his co-authors in the latest issue of Deutsches Ärzteblatt International.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Sarah E Nicholas, MD Banner Md Anderson Cancer Center, 2946 E. Banner Gateway Drive, Gilbert, AZ 85234 Ph: (480) 256-6444 | Sarah E Nicholas, MD Banner Md Anderson Cancer Center, 2946 E. Banner Gateway Drive, Gilbert, AZ 85234 Ph: (480) 256-6444 |
News Archive
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, presented new pre-clinical data from its ALN-TTR program at the XII International Symposium on Amyloidosis in Rome on April 18 - 21, 2010. ALN-TTR01 is a systemically delivered RNAi therapeutic being developed for the treatment of transthyretin (TTR)-mediated amyloidosis (ATTR), including familial amyloidotic polyneuropathy (FAP) and familial amyloidotic cardiomyopathy (FAC).
Auxilium Pharmaceuticals, Inc., a fully integrated specialty biopharmaceutical company, today announced financial results for the fourth quarter and full year ending December 31, 2013. The Company also highlighted select commercial, regulatory and clinical development progress and future goals and provided financial guidance for 2014.
Also, news outlets examine the idea that the expansion's new enrollees will likely be healthier than current beneficiaries but this will probably not relieve the expansion's pressure on the health care workforce.
The U.S. Food and Drug Administration has accepted an Investigational New Drug application by physician-scientists at University of California San Diego School of Medicine to conduct the first U.S. clinical trial of an intravenously administered bacteriophage-based therapy.
Therapeutic hypnosis is an effective and safe complementary technique in surgery and the treatment of irritable bowel syndrome. This is the conclusion of a systematic review by Winfried Häuser and his co-authors in the latest issue of Deutsches Ärzteblatt International.
› Verified 6 days ago
Dr. Georg Hernandez, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 4001 E Baseline Rd Ste 105, Gilbert, AZ 85234 Phone: 480-632-5378 Fax: 480-632-1821 | |
Yerko O Borghero, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 2940 E Banner Gateway Dr, Suite 450, Gilbert, AZ 85234 Phone: 480-256-3676 Fax: 480-256-3608 | |
Dr. Joel R Meyer, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: Banner Md Anderson Cancer Center, 2940 E. Banner Gateway Drive Suite 350, Gilbert, AZ 85234 Phone: 480-256-6444 Fax: 480-256-3682 | |
Dr. Matthew D Callister, M.D. Radiology Medicare: Medicare Enrolled Practice Location: 2940 E Banner Gateway Dr, Suite 450, Gilbert, AZ 85234 Phone: 480-256-6444 | |
Dr. Philippe Lanauze, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 2946 E Banner Gateway Dr., Gilbert, AZ 85234 Phone: 480-256-6444 Fax: 480-256-4683 | |
Gary Walker, M.D., M.P.H., M.S. Radiology Medicare: Accepting Medicare Assignments Practice Location: 2946 E Banner Gateway Dr, Gilbert, AZ 85234 Phone: 480-256-4500 |